What is Aducanumab?

Aducanumab (Aducanumab) is a drug used to treat Alzheimer's disease, a common neurodegenerative disease that usually occurs in older adults and is characterized by cognitive impairment, memory loss, and impairment of daily activities. Alzheimer's disease is an irreversible disease, and its treatment has always been a difficult problem in the medical field.

Aducanumab uses an innovative treatment method, and its mechanism of action mainly involves the removal of βamyloid plaques (beta-amyloid plaques) in the brain. These plaques are the hallmark pathological feature of Alzheimer's disease and are thought to be related to the progression of the disease and nerve cell damage. Aducanumab slows the progression of the disease by binding to and clearing these plaques, providing a new treatment option.

Aducanumab belongs to a class of drugs called antibody drugs, which are highly specific and can selectively bind to β amyloid plaques and reduce their accumulation in the brain. This mechanism of action has the potential benefit of improving patients' cognitive function, alleviating symptoms, and potentially improving patients' quality of life.

However, aducanumab is not without side effects. During use, patients may experience some adverse reactions, including skin reactions, headaches, nausea and vomiting. In addition, the drug may increase the risk of cerebral hemorrhage, especially in patients with pre-existing cerebrovascular disease or other risk factors for bleeding.

Therefore, the use of aducanumab needs to be under the guidance of a physician, who will weigh the potential benefits and risks based on the patient's specific situation and risk factors. Additionally, medications often require regular monitoring to ensure their safety and effectiveness.